Sponsor hub
Fox Chase Cancer Center clinical trial failures
Review 35 stopped clinical trials from Fox Chase Cancer Center, including disease areas, phases, and classified stop reasons.
This page groups real ClinicalTrials.gov-derived stopped trial records. The strongest added signal is the stop-reason classification: 4 of these records are likely biological failure signals, while the rest may reflect operational, strategic, regulatory, funding, enrollment, or unclear stop reasons.
Dominant stop reasons
- OPERATIONAL
- 18
- OTHER/UNKNOWN
- 13
- EFFICACY/FUTILITY
- 2
- SAFETY
- 2
Notable sponsors
- Fox Chase Cancer Center
- 35
Related phases
- Phase II
- 20
- Phase I
- 11
- Unknown
- 3
- Early Phase I
- 1
Crawlable stopped-trial records
Open ExploreShowing up to 35 representative records from this slice. Each link opens the trial detail page with source attribution and stop-reason context.
Phase I Solid Tumor trial by Fox Chase Cancer Center. Stop reason: OTHER/UNKNOWN.
Study drug availability
Phase II Small-cell Lung Cancer trial by Fox Chase Cancer Center. Stop reason: OPERATIONAL.
Closed to accrual due to low probability of successful outcomes
Phase II Endometrial Cancer trial by Fox Chase Cancer Center. Stop reason: OPERATIONAL.
Slow accrual
Phase I Recurrent Fallopian Tube Cancer trial by Fox Chase Cancer Center. Stop reason: OTHER/UNKNOWN.
Study drug is no longer supplied by grantor.
Phase II Lymphoma trial by Fox Chase Cancer Center. Stop reason: OPERATIONAL.
To be terminated due to slow accrual, patient still in follow up
Phase II Major Liver Resection trial by Fox Chase Cancer Center. Stop reason: OTHER/UNKNOWN.
Grantor closed study
Phase II Metastatic Urothelial Carcinoma trial by Fox Chase Cancer Center. Stop reason: OTHER/UNKNOWN.
Change in standard of care.
Phase II Non-Small Cell Lung Cancer trial by Fox Chase Cancer Center. Stop reason: OPERATIONAL.
Grantor withdrew support due to slow accrual
Phase I Recurrent Metastatic Squamous Neck Cancer With Occult Primary trial by Fox Chase Cancer Center. Stop reason: OPERATIONAL.
Pharmaceutical co. withdrew support. Study was never activated and did not accrue any patients.
Phase II Sporadic Angiomyolipomas (AMLs) trial by Fox Chase Cancer Center. Stop reason: SAFETY.
Extreme toxicity, met toxicity stopping rules
Phase II Soft-tissue Sarcoma trial by Fox Chase Cancer Center. Stop reason: OPERATIONAL.
Closed to accrual due to Funding Sponsor withdrawing support due to low accrual
Phase II Head and Neck Cancer trial by Fox Chase Cancer Center. Stop reason: EFFICACY/FUTILITY.
stopped for lack of efficacy
Phase I Lymphoma, T-Cell, Peripheral trial by Fox Chase Cancer Center. Stop reason: OTHER/UNKNOWN.
Merck no longer providing drug for study
Phase II Esophageal Stenosis trial by Fox Chase Cancer Center. Stop reason: OTHER/UNKNOWN.
Study was not approved for Fox Chase Cancer Center's Research Review Committee (RRC)
Phase II Colorectal Cancer trial by Fox Chase Cancer Center. Stop reason: OPERATIONAL.
Administrative change
Phase II Colorectal Neoplasms trial by Fox Chase Cancer Center. Stop reason: OPERATIONAL.
Enrollment closed 10/15/2008 based on data about KRAS.
Phase I Relapsed or Refractory Solid Tumors trial by Fox Chase Cancer Center. Stop reason: OPERATIONAL.
Study terminated prematurely due to funding/support being withdrawn by grantor
Phase I Colorectal Adenocarcinoma trial by Fox Chase Cancer Center. Stop reason: OTHER/UNKNOWN.
The single Quinacrine manufacture facility in the US was shut down by the FDA
Phase I Acute Myeloid Leukemia trial by Fox Chase Cancer Center. Stop reason: OPERATIONAL.
Slow accrual
Unknown Metastatic Colorectal Cancer trial by Fox Chase Cancer Center. Stop reason: OPERATIONAL.
Slow accrual
Phase II Pancreatic Cancer trial by Fox Chase Cancer Center. Stop reason: EFFICACY/FUTILITY.
Stopped accordining to early stopping rule for futility
Unknown BRCA1 Mutation trial by Fox Chase Cancer Center. Stop reason: OPERATIONAL.
Unable to recruit volunteers
Phase II Anaplastic Large Cell Lymphoma, ALK-Positive trial by Fox Chase Cancer Center. Stop reason: OPERATIONAL.
Slow accrual
Phase II Non Small Cell Lung Cancer Stage IIIB trial by Fox Chase Cancer Center. Stop reason: OTHER/UNKNOWN.
Unable to accrue subjects
Phase I Metastatic Renal Cell Carcinoma trial by Fox Chase Cancer Center. Stop reason: OTHER/UNKNOWN.
IRB study closure facilitated by Investigator
Unknown Malignant Pericardial Effusion trial by Fox Chase Cancer Center. Stop reason: OPERATIONAL.
Feasibility
Phase I Acinar Cell Adenocarcinoma of the Pancreas trial by Fox Chase Cancer Center. Stop reason: OPERATIONAL.
Slow accrual
Phase II Distal Urethral Cancer trial by Fox Chase Cancer Center. Stop reason: SAFETY.
Extreme Toxicity
Early Phase I Squamous Cell Carcinoma of the Head and Neck trial by Fox Chase Cancer Center. Stop reason: OPERATIONAL.
Slow accrual
Phase I Ovarian Papillary Serous Carcinoma trial by Fox Chase Cancer Center. Stop reason: OPERATIONAL.
study was never opened to accrual
Phase II Recurrent/ Metastatic Endometrial Carcinoma trial by Fox Chase Cancer Center. Stop reason: OTHER/UNKNOWN.
Sponsors pulled out of the study
Phase I Non-small Cell Lung Cancer Metastatic trial by Fox Chase Cancer Center. Stop reason: OTHER/UNKNOWN.
Phase I portion completed. Phase II will open pending amendment approval.
Phase II GIST trial by Fox Chase Cancer Center. Stop reason: OTHER/UNKNOWN.
Novartis is ending their research program for Nilotinib in GIST.
Phase II Contiguous Stage II Adult Diffuse Large Cell Lymphoma trial by Fox Chase Cancer Center. Stop reason: OPERATIONAL.
No Funding Source and Competing Trials
Phase II Prostate Cancer trial by Fox Chase Cancer Center. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.